ClearPath retweeted
Biology is not just a Rube Goldberg Turing Machine but so much more, because when you look at what the molecules really are and how they push - why it's electric forces, and the chemical bonds are electronic too, and all these molecules and atoms are bathed in a common sea of electromagnetism that does not just travel fast rather it defines the speed of causality.
And that these chemical bonds and molecular rotations all vibrate, DC electric fields wiggling into AC fields, and these AC fields travel as photons and land as phonons heating things up, making and breaking bonds, changing their shape, we feel this as heat, as light, and our bodies are made of towering stacks of electronic bonds each with its own energy level that are so closely spaced as to be continuous, and all these bonds and molecules vibrating and emitting and absorbing constitute a constant exchange of field energy and information with the towering stacks of electronic bonds in our surroundings, like tall ships with endless stories of cannons exchanging electromagnetic broadsides in both directions at once, at all times, along minimal paths in spacetime, at quantized energy levels.
And you'd rightly think this is all wondrously mad and fantastical and surely just a mathematical model and I say no - this is sight, this is what it means to see, both literally and figuratively, to know that your experience is constituted by electromagnetic field interaction in its entirety, and these same fields are what planets, stars, everything is made of, and when you open two quarter sized holes in your head and let it all in this is what you *see*. The world as constructed in your mind, the surface of your retina coupled to the surface of the wall, a cloud, a distant galaxy by a field wiggling both ends at once.
Now you consider all these things and what energy means, and how it flows through the body and the air and environment as a currency animating dead matter into life, that it comes from the Sun, ultimately, crushing protons into Helium and bathing the solar system in it's electromagnetic field of life giving energy, passed as photons and minted by chloroplasts into sugar, and if you really start to visualize and understand the true nature of what you're in, what the constituent building blocks of everyday experience actually turn out to be in the details, then you know for certain that humans are like children playing on the shore of an ocean so deep and wide as to make our greatest imagination and dreams seem shallow.
And that the laws of nature are as much for our discovery as we are to be a discovery of the universe getting to know itself.
ClearPath retweeted
$QURE’s platform franchise era has officially begun. A 1 of 1 HD asset and more to come. Stay tuned.
ClearPath retweeted
Not many people seem to know about Metaplanet, Jaan Tallinn's VC firm.
They are the most AGI-pilled firm on the planet, and are about to flip many of the tier 1s.
> Invested in @GoogleDeepMind in 2011
> Led @AnthropicAI series A in 2021
> Doubled down on Anthropic in every round since. IRR hurdle for deploying capital into anything else was {absurdly high number}% for years
> Anchored the premier AGI hedge funds (+Mythos) + in-house public equities strategy
4-person team in Estonia now managing 10s of billions AUM, liquid after $ANT IPO.
Rationalist roots --> zero bureaucracy, cares about human survival & flourishing as north star, doesn't care who else is investing or how high status a founder / idea is
Founders: congrats! you no longer need to play status games to raise a mega round for your civilization-scale moonshot. You can just pitch @metaplanetfund
ClearPath retweeted
Revenue per GPU can increase as token prices decline if per GPU token throughput increases enough.
So both Anthropic revenue *and* margins can go up as token prices go down *if* GPU prices go up less than the product of (token price decline * per GPU throughput increase).
But I have super enjoyed all the commentary to the contrary!
ClearPath retweeted
Adam the contrast was the point. Two different bad/fatal diseases yet very different response from the field to advances. We do not have a functional cure for many cancers but HR < .7 in any cancer is described as practice changing in oncology. Neurology seems underwhelmed by the same degree in disease change.
Of course cancer is not one thing and I could have been more precise- CLL is not good but now mostly not fatal, due to many advances from Lilly and our peers HR+ HER - breast cancer has long survival now yet GI cancers are mostly unsolved and survival curves are terrible.
You know what else is terrible? Almost every neuro-degenerative disease including AD and we (including the media) need to discuss it that way. Unfortunately I’ve witnessed end of life journeys up close in both diseases, while different horrors present themselves in each I’d say they are both pretty bad. Advancement 30%+ at a time should change practice and routinely be offered to patients and families. Oncology does this Neurology doesn’t.
$LLY Kisunla is an Alzheimer's drug. It's not a cancer drug. Different diseases, different trajectories, different patient population with different needs, different benefit-risk profile.
@DaveARicks, speaking to @bradloncar, points to the hazard ratio from Kisunla's Phase 3 studies and says, "If this was a cancer drug, it would be a giant drug!"
Ok, but it's not.
ClearPath retweeted
Cool!
In partnership with Vinod Khosla (@vkhosla), I’m proud to introduce Reservoir.
Billionaires have owned their cells for years. Starting today, you can too.
Sign up today: withreservoir.com
ClearPath retweeted
$qure $clpt
The new framework is intended to enable patient input at earlier stages and at milestones throughout the development and review process. It also aims to provide greater clarity and consistency to drug developers on regulatory decision making. The agency said in a statement that it should take into account what evidence is reasonably attainable, given the nature of rare diseases.
New: FDA leadership is kicking off a top-to-bottom review of how it approaches approvals for drugs to treat rare diseases. The Rare Disease Framework Initiative will kick off with a meeting on Oct. 28
w/ @RobertLangreth
🎁: bloomberg.com/news/articles/…
ClearPath retweeted
My thoughts on why I believe QURE has cleared the bar. Free post below.
botn.bio/p/the-three-year-qu…
ClearPath retweeted
👇👇👇
Replying to @Vulpescap
And why wouldn’t it get approved? The endpoint submitted for approval is stat Sig, as was the key secondary that will serve as the confirmatory primary.
I actually have a hard time seeing how people think this gets shut out with the current admin/setup?
ClearPath retweeted
Okay, so $QURE just got crushed nearly 40%, and a lot of people are reading that as the Huntington’s gene therapy falling apart at year four. I don’t think that’s what’s going on.
What’s actually wild here is the comparison group. By year four, about half of those patients were gone from the data, and the ones who left were getting sicker faster. Leave them out and the remaining controls look healthier, so the drug looks weaker even when the treated patients themselves have not suddenly fallen apart.
That pattern shows up all over medicine, and most people never see it. When a trial cannot ethically leave patients untreated for years, companies often borrow a “control” from a big natural-history database: people with the same disease, matched on paper, who were simply followed over time. It is a clever workaround. It is also fragile. The people who stay in those databases long enough to be counted at year four are not a random sample of the disease. The ones who get worse faster drop out, move to hospice, miss visits, or die. What remains is a quieter, healthier-looking average. Compare a real treated group to that thinned-out average and you can manufacture a “fade” that is partly just the control getting easier to beat.
Huntington’s makes this especially sharp. As most of you know, it comes from one broken gene. That gene builds a sticky huntingtin protein that slowly wrecks the brain, and we still have nothing approved that puts the brakes on that decline. AMT-130, now named ifezuntirgene inilparvovec, tries something blunt and beautiful: one surgery, one dose into the striatum, the deep brain region this disease hits early, and a tiny designed RNA that tells cells to make less huntingtin.
The high-dose group here is tiny, so every number needs humility. At three years, now with 15 people, the main disease score (thinking, movement, and day-to-day function rolled together) got about 80% less worse than matched people watched in that natural-history database. That three-year cut is what the company put in its filing with @FDA. At four years, 12 of those patients were still on that same score, and the slowing fell to 44%. It missed the usual statistical bar (p=0.144). The score that asks a simpler question, can you still work, manage a house, take care of yourself, still looked better: about 61% less decline (nominal p=0.008). That everyday-function score is also what the bigger confirmatory trial will lead with.
And look at what happened underneath those percentages. By month 48, 53% of the matched comparison patients had missing follow-up. The ones who vanished were declining faster than the ones who stayed. If the sickest untreated people leave the spreadsheet, the remaining “no-drug” group looks healthier than real Huntington’s usually does. The gap between drug and no-drug then shrinks on paper. When the company ran the same four-year patients against an older version of that control set, the slowing on the main score came back near 54%. Same treated people. Different ghost of a control. Different story.
To me the sell-off looks like traders bracing for a messier approval path, not like the biology flipped overnight. Twelve patients cannot settle how long a benefit lasts. What this episode can settle is a harder habit: before you trust a year-four “fade,” ask who is still left in the untreated column.
What I am sure is that I truly hate all brain diseases. Disease in general is bad, yes. But brain diseases deserve our special hatred. We should unite as humanity to beat all brain diseases as quickly as possible. That I know...
ClearPath retweeted
$QURE uniQure weakness creates attractive opportunity, says Wells Fargo, Reiterates Buy PT $75





































